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Summary 41 
Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike 42 
(S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. 43 
We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from 44 
COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent 45 
sites on the RBD and, unlike its parental antibodies, prevents detectable S binding to Angiotensin-46 
Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 neutralizes 47 
SARS-CoV-2 and its variants of concern, as well as the escape mutants generated by the parental 48 
monoclonals. In a novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-49 
X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-50 
overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining 51 
into a single molecule the advantages of antibody cocktails.  52 
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The COVID-19 pandemic prompted an unprecedented effort to develop effective countermeasures 54 
against SARS-CoV-2. Pre-clinical data and phase III clinical studies indicate that monoclonal 55 
antibodies (mAbs) could be effectively deployed for prevention or treatment during the viral 56 
symptoms phase of the disease1,2. Cocktails of two or more mAbs are preferred over a single 57 
antibody for increased efficacy and prevention of viral escape. However, this approach requires 58 
increased manufacturing costs and volumes, which are problematic at a time when the supply chain 59 
is under pressure to meet the high demand for COVID-19 therapeutics, vaccines and biologics in 60 
general4. Cocktails also complicate formulation5,6 and hinder novel strategies like antibody 61 
delivery by viral vectors or by non-vectored nucleic acids7-9. Instead, multispecific antibodies 62 
embody the advantages of a cocktail within a single molecule.  63 
To this avail, we employed structural information10 and computational simulations to 64 
design bispecifics that would simultaneously bind to (i) independent sites on the same RBD and 65 
(ii) distinct RBDs on a S trimer. Out of several designs evaluated by atomistic Molecular Dynamics 66 
simulations, 4 were produced and CoV-X2 was the most potent neutralizer of SARS-CoV-2 67 
pseudovirus, with half-maximal inhibitory concentration (IC50) = 0.04 nM (5.8 ng/mL) (Extended 68 
Data Fig.1). CoV-X2 is a human-derived, CrossMAb-format IgG1-like bispecific antibody11 69 
resulting from the combination of the Fragment antigen binding (Fab) of mAbs C121 and C135, 70 
two potent SARS-CoV-2 neutralizers3. Structural predictions showed that CoV-X2, but not its 71 
parental monoclonals, can bind bivalently to all RBD conformations on the S trimer, preventing 72 
ACE2 access (Fig.1a and Extended Data Fig.2)12.  73 
CoV-X2 bound with low nanomolar affinity to RBD, S trimer, and to several mutants, 74 
including the naturally occurring variants B.1 (D614G in S protein), B.1.1.7 (N501Y in RBD) and 75 
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B.1.351 (K417N, E484K and N501Y in RBD)13,14, and the escape mutants of the parental mAbs15 76 
(Extended Data Figs.3-5).  77 
 78 
Fig.1 | Biochemical and in vitro neutralizing properties of CoV-X2 are superior to its parental mAbs. 79 
a, Computational simulations predict bivalent binding of CoV-X2 to all three RBDs on the S trimer (see 80 
also Extended Data Fig.2). Green and blue are C121 and C135 moieties, respectively; RBDs are in shades 81 
of yellow/orange. b, c, SPR demonstrates that both arms of CoV-X2 are functional. In (b), immobilized 82 
RBD complexed with the indicated mAb (first antibody) binds to CoV-X2 (second antibody). In (c), the 83 
RBD/CoV-X2 complex prevents binding by the single mAbs. Shaded colors are controls (second antibody 84 
only). d, Both arms of CoV-X2 bind simultaneously to the RBD since, contrary to the monoclonals, avidity 85 
is retained at decreasing RBD concentrations. On top, representative SPR traces indicating the different 86 
dissociations of antibodies (or Fab) binding to RBD immobilized at different concentrations on the SPR 87 
chip (see also Extended Data Fig.6). At the bottom, plots of the normalized ka and kd values obtained with 88 
different concentrations of immobilized RBD. Increasing normalized dissociation rate (kd) values indicate 89 
loss of avidity. e, f, CoV-X2 fully prevents ACE2 binding to S trimer in ELISA. ACE2 binding to 90 
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antibody/S trimer complexes is measured either with increasing concentration of the indicated antibody and 91 
constant ACE2 (e), or at constant antibody concentration with increasing ACE2 (f). Mean with standard 92 
deviation of two experiments is shown. g, CoV-X2 neutralizes SARS-CoV-2 pseudovirus and escape 93 
mutants of its parental mAbs. Normalized relative luminescence (RLU) for cell lysates after infection with 94 
nanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasing concentrations of antibodies. 95 
Wild-type SARS-CoV-2 pseudovirus (left) is shown alongside three escape mutants generated in the 96 
presence of C121 or C13515. Dashed lines are parental Fabs. Mean with standard deviation; one of two 97 
independent experiments. h, Neutralization of SARS-CoV-2 isolates with sequences corresponding to 98 
viruses first isolated in China (wild-type), Italy (D614G), United Kingdom (UK; B.1.1.7), Brazil (BRA; 99 
B.1.1.248) and South Africa (SAF; B.1.351). RBD residues mutated in the variants are indicated in the 100 




CoV-X2 also bound to pre-formed C121/RBD and C135/RBD complexes, thus confirming 105 
that both of its arms are functional (Fig.1b,c). Next, an avidity assay by Surface Plasmon 106 
Resonance (SPR) was used to experimentally confirm the computational prediction that CoV-X2 107 
can simultaneously engage two sites on the same RBD (Methods, Fig.1d and Extended Data Fig.6). 108 
Avidity occurs when IgGs bind bivalently to antigens, resulting in slower dissociation rates (kd) 109 
(Extended Data Fig.6a). Accordingly, C121 and C135 IgG showed avidity at high antigen 110 
concentrations due to inter-molecular binding of adjacent RBDs; at lower antigen concentrations 111 
the dissociation rate was instead faster since inter-molecular binding was prevented by the 112 
increased distance between RBD molecules, resulting in loss of avidity. Intra-molecular avidity is 113 
not possible for C121 and C135 since a single epitope is available on each RBD molecule. By 114 
contrast, CoV-X2 maintained avidity even at low antigen concentrations, indicating bivalent, intra-115 
molecular binding (Fig.1d and Extended Data Fig.6). ELISA assays were then performed to 116 
evaluate the ability of CoV-X2 to inhibit the binding of recombinant ACE2 to the S trimer 117 
(Fig.1e,f). In line with the structural information10, C135 did not affect the ACE2/S interaction. 118 
C121, which occupies the ACE2 binding site on the RBD, prevented ACE2 binding but only 119 
partially. By contrast, ACE2 binding was not detected in the presence of CoV-X2, suggesting a 120 
synergistic effect by the two moieties composing the bispecific. 121 
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To assess the neutralizing ability of CoV-X2 in vitro, we first used SARS-CoV-2 122 
pseudoviruses16. The bispecific neutralized pseudovirus carrying wild-type SARS-CoV-2 S at sub-123 
nanomolar concentrations (IC50 = 0.04 nM (5.8 ng/mL); IC90 = 0.3 nM (44 ng/mL)), which was 124 
similar or better than the parental IgGs and >100-fold better IC50 than the parental Fabs (Fig.1g). 125 
CoV-X2 remained effective against pseudoviruses bearing escape mutations that made them 126 
resistant to the individual mAbs (Fig.1g)15 and against a pseudovirus with RBD mutations found 127 
in the B.1.351 variant (first reported in South Africa, IC50 =1.3 nM (191 ng/mL); Extended data 128 
Fig. 5). To confirm CoV-X2 efficacy, we performed plaque reduction neutralization assays with 129 
infectious virus. CoV-X2 efficiently neutralized: SARS-CoV-2 (IC50 = 0.9 nM); the D614G variant 130 
first appearing in Europe (B.1, IC50 = 0.2 nM); the B.1.1.7 variant first observed in the United 131 
Kingdom (IC50 = 0.2 nM); the B.1.1.248 variant first isolated in Brazil (IC50 = 2.1 nM) and B.1.351 132 
first isolated in South Africa (IC50 = 12 nM; Fig.1h). The latter two have almost identical mutations 133 
in the RBD, the only difference being N vs. T at position 417, which does not interact with 134 
CoV-X2. Nonetheless, neutralization of B.1.351 was lower, suggesting either some 135 
conformational differences in the RBD or long-range effects deriving from other mutations in the 136 
S protein. A similar behavior is seen with the wild-type sequence (D614), which has lower 137 
neutralization than G614 even if no other difference is present; a plausible explanation is that G614 138 
makes the CoV-X2 epitopes more accessible by favoring the RBD ‘up’ conformation.17 We 139 
conclude that the in vitro binding and neutralizing properties of CoV-X2 make it preferable over 140 
its parental antibodies. 141 
To assess the clinical potential of CoV-X2, we investigated its ability to protect animals 142 
from infection and disease. We first developed a novel mouse model in which human ACE2 143 
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(hACE2) is expressed by upper and lower respiratory tract cells upon inhalation of a modified 144 
Adeno Associated Virus (AAV-hACE2, see Methods, Fig.2 and Extended Data Fig.7). 145 
 146 
Fig.2 | CoV-X2 protects AAV-hACE2-transduced mice against SARS-CoV-2 disease. a, Loss of body 147 
weight over time in SARS-CoV-2 infected mice. 13 to 15 weeks old C57Bl/6NCrl wild-type female mice 148 
were transduced with AAV-hACE2 by forced inhalation, which provides delivery of viral particles to both 149 
upper and lower respiratory tract. After >7 days, mice were either infected with SARS-CoV-2 (1x104 pfu) 150 
or received vehiculum by the intranasal route. Weight was monitored daily for 8 days (SARS-CoV-2, n = 151 
5; control, n = 4). Mean with standard deviation is shown. b, Kinetic of viral burden in the lungs from 152 
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 8 
SARS-CoV-2-infected mice by plaque assays. Mean with standard deviation; the dashed line indicates the 153 
limit of detection. c, Kinetic of viral RNA levels in lung samples from SARS-CoV-2-infected mice by RT-154 
qPCR. Mean with standard deviation. d, Schematic of the experimental layout. Wild-type mice were 155 
transduced with AAV-hACE2 by forced inhalation. After >7 days, mice were inoculated intraperitoneally 156 
(i.p) with 150 µg of antibodies. One day later, the mice were infected intranasally (i.n.) with SARS-CoV-2 157 
(1x104 pfu). e, Changes in body weight upon infection were monitored daily in antibody-treated mice 158 
(C121, n=9; C135, n=5; CoV-X2, n=13; isotype control, n=10). Mean with standard deviation is shown. f, 159 
Lung viral burden by plaque assay at 5 dpi (isotype control, n=6; CoV-X2, n=10). The dashed line indicates 160 
the limit of detection; mean with standard deviation. P value was calculated with two-tailed Student’s t test. 161 
g, Spleen viral RNA levels by RT-qPCR at 5 and 8 dpi (gray: isotype control; purple: CoV-X2). Mean with 162 
standard deviation. P value was calculated with two-tailed Student’s t test. h, Photographs of lungs collected 163 
from infected mice (8 dpi). i, Histopathology and F4/80 immunohistochemistry (IHC). Hematoxylin and 164 
Eosin-stained (H&E) sections of paraffin-embedded lungs from infected mice (8 dpi). Arrowheads point to 165 
foamy macrophages. F4/80 IHC shows abundant macrophage infiltration in lungs of mice treated with 166 
isotype control but not with CoV-X2. 167 
 168 
This approach enables rapid production of large cohorts of animals and has the advantage of being 169 
applicable to wild-type and mutant mouse colonies, independently of age and gender. Moreover, 170 
since AAV vectors are only weakly immunogenic and cytotoxic, the system allows for prolonged 171 
expression of hACE218-21 (Extended Data Fig.7). SARS-CoV-2 infection of ACE2 humanized 172 
mice results in progressive weight loss, respiratory pathology and disease requiring culling on day 173 
8 post infection (dpi, Fig.2a–c and Extended Data Fig.7). 174 
To evaluate the protective effect of antibodies, hACE2 mice were treated with antibody 175 
(150 µg) one day before SARS-CoV-2 challenge and monitored over time (Fig.2d–i). Upon 176 
intranasal infection with 1x104 pfu of SARS-CoV-2 (SARS-CoV-2/human/Czech 177 
Republic/951/2020), isotype control treated animals showed weight loss starting at 3 dpi, and by 178 
8 dpi most animals had lost approximately 25–30% of their body weight reaching humane endpoint 179 
(Fig.2e). Infectious virus could be recovered from the lungs (Fig.2f), viral RNA was detected also 180 
in the spleen (Fig.2g) but not in the heart (data not shown). Lung pathology resembled severe 181 
COVID-19 in humans22 and was characterized by Diffuse Alveolar Damage (DAD; 50-80% of 182 
tissue area),  alveolar replacement with infiltrates of immune cells and fibroblasts, thickened septa 183 
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and infiltrations by activated macrophages with foamy cytoplasm (Fig.2i). In contrast, animals 184 
treated with CoV-X2 maintained their body weight (P<0.0001 at 4–8 dpi when compared to 185 
isotype; Fig.2e; P values between all groups in Extended Data Table1), had reduced viral RNA in 186 
the spleen (Fig.2g) and displayed neither macro- nor histopathological changes (DAD <5-10%, 187 
Fig.2h,i). While infectious virus could be readily recovered from controls (5 of 6), it was only 188 
recovered from 1 out of 10 CoV-X2 treated animals at 5 dpi (Fig. 2f) and could not be recovered 189 
from any of 13 animals at 8 dpi (data not shown). Since none of the CoV-X2 treated mice exhibited 190 
symptoms at any time, we conclude that CoV-X2 protects mice from infection and disease.  191 
Since monotherapy with C121 or C135 mAbs leads to virus escape in vitro15, we treated 192 
hACE2 mice with the individual antibodies and sequenced the virus. Only wild-type RBD 193 
sequences were obtained from controls (n=10). Instead, the virus in mice treated with C121 194 
selected for a mutation resulting in E484D (5 of 5 mice that were analyzed at 8 dpi). C121 escape 195 
mutations at E484 were previously observed in vitro15 and changes at this residue (present also in 196 
the B.1.351 and B.1.1.248 variants) reduce neutralization by human sera by more than 10-fold23. 197 
E484D affects intermolecular H-bonds at the core of the C121/RBD interface and it is suggested 198 
to increase the RBD affinity for ACE224. Virus with D484 is pathogenic, since 7 out of 9 mice 199 
treated with C121 developed disease (Fig.2e) and only D484 virus was found in their lungs. In 200 
contrast, and unlike the in vitro results15, no virus evasion or pathology was observed in mice 201 
treated with C135 (n=5; Fig.2e and data not shown). In CoV-X2 treated animals, even though no 202 
infectious virus was retrieved (8 dpi, n=13) and no symptoms ever noticed, low levels of residual 203 
viral RNA could be detected in some animals after 40 cycles of PCR amplification: in 6 of 13 204 
animals the virus sequence was wild-type and in 2 mice overlapping sequencing traces were 205 
consistent with coexistence of wild-type and D484. Thus, in those 2 of 13 animals with D484 CoV-206 
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X2 remained protective even if the mutation diluted the effective antibody concentration, 207 
presumably leaving only the C135 moiety active. Finally, CoV-X2 was protective also when 208 
administered 12 hours after SARS-CoV-2 challenge (Extended Data Fig.8) 209 
Monoclonal antibodies targeting the SARS-CoV-2 S are in advanced clinical trials and 210 
show promise against COVID-191,2. Concomitant use of multiple antibodies is preferred for 211 
increased efficacy and added resistance against viral evasion. Indeed, the virus can escape pressure 212 
by a single antibody in vitro and, as shown here, also in animals. Moreover, RBD mutations 213 
threatening the efficacy of single monoclonals have already been detected in virus circulating in 214 
minks and humans25, including mutations at the C121 and C135 epitopes (Extended Data Fig.9). 215 
One disadvantage of antibody cocktails is the requirement for twice or more the development and 216 
production capacity than for single mAbs, which is a significant challenge in light of the 217 
augmented demand due to COVID-19 related vaccines and therapeutics on top of the need to 218 
maintain production of biologics for other diseases.4 219 
Multispecific antibodies offer the advantages of cocktails in a single molecule. Indeed, we 220 
have shown that the CoV-X2 bispecific is more effective than the related monoclonals at inhibiting 221 
ACE2 binding; it has sub-nanomolar IC50 against a broader array of viral sequences; and it protects 222 
animals from SARS-CoV-2 even when C121, its potent parental mAb, fails due to the insurgence 223 
of viral escape. C135, the other parental mAb, did not generate escape in our animal experiment 224 
but readily generated them in vitro15. CoV-X2 is expected to be more resistant to viral escape 225 
compared to monoclonals. Indeed, we have shown that CoV-X2 binds and neutralizes mutants not 226 
recognized by its parental mAbs as well as variants of concern that recently emerged in United 227 
Kingdom13, South Africa14 and Brazil26. 228 
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CoV-X2, unlike other multispecifics27, is a fully human IgG-like molecule. As such, it has 229 
favorable developability and could be further engineered to alter effector functions. For example, 230 
the Fragment crystallizable (Fc) of CoV-X2 was already modified to modulate its interaction with 231 
Fc receptors and complement (LALA-PG mutations)28 without affecting its antigen-binding 232 
properties. The LALA modification prevents Antibody Dependent Enhancement (ADE) of 233 
flavivirus infection29,30 and it may be a desirable modification also in the context of SARS-CoV-234 
2, since cellular and animal experiments with coronaviruses, including SARS-CoV31-33, support 235 
the possibility of ADE. Other modifications, like LS28 for increased half-life, are easily achievable. 236 
Finally, CoV-X2 is human-derived and produced in a format (CrossMab) already shown to be safe 237 
in clinical trials34, which further supports its developability. Thus, IgG-like bispecifics are worth 238 
adding to the arsenal employed to combat SARS-CoV-2 and its plausible future mutations.  239 
 240 
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Extended data figures 360 
 361 
Extended Data Fig.1 | Neutralization of SARS-CoV-2 pseudovirus by bispecific antibodies. a, 362 
Schematic representation of the 4 bispecific constructs; two in scFv format and two as IgG-like CrossMAb 363 
with knob-in-hole. The parental monoclonals forming the bispecifics are color-coded (C135 blue, C144 364 
orange, C121 green; Fc region in purple). b, All 4 constructs neutralize SARS-CoV-2 pseudovirus in vitro 365 
at sub-nanomolar concentrations (IC50: 0.13, 0.04, 0.74 and 0.53 nM for CoV-X1, CoV-X2, CoV-scB1 and 366 
CoV-scB2, respectively). Normalized relative luminescence values, which correlate to infection, are 367 
reported versus antibody concentration, as detailed in Schmidt et al.16. Mean with standard deviation is 368 
shown, representative of two independent experiments.  369 
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 370 
Extended Data Fig.2 | CoV-X2 engages its epitopes on all RBD conformations on the S trimer. a–d, 371 
Molecular Dynamics (MD) simulations of the complex between the CoV-X2 bispecific and S trimers with 372 
RBD in either all down, all up or mixed up/down conformations show that CoV-X2 can engage a single 373 
RBD with both arms (a,b), two adjacent RBDs in the down conformation (c), and two RBDs in the up/down 374 
conformation (b,d). The complexes were subjected to up to 400 ns of fully atomistic MD simulations to 375 
assess feasibility and stability of the bound conformations. Root-mean-squared deviations (RMSD) values 376 
are shown to indicate structural stability. S trimer is in shades of grey, RBDs in yellow (down conformation) 377 
and orange (up), the C121 and C135 moieties of CoV-X2 are in green and blue, respectively. e, Schematic 378 
representation of the computationally predicted binding modes of CoV-X2, C121 IgG and C135 IgG on the 379 
S trimer, colored as in a–d. Antibodies are represented by connected circles; ACE2 is in red on the RBD if 380 
it can bind directly to a given conformation; it has an arrow pointing to the RBD if ACE2 binding is 381 
achieved after an allowed switch to the up conformation. For example, in the 3-up conformation (left), 382 
CoV-X2 can engage all the RBDs with bivalent binding, whereas C121 and C135 can only achieve 383 
monovalent binding. C135 binding does not prevent interaction with ACE2. The situation is similar in the 384 
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other S conformations (2-up 1-down, 2-down 1-up and 3-down), with only the bispecific achieving bivalent 385 
interaction and preventing ACE2 access in all conformations.  386 
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 387 
Extended Data Fig.3 | CoV-X2 and its parental mAbs bind recombinant, isolated RBD and S trimer 388 
with low nanomolar affinity. a, Representative SPR traces from which the data in (b) was derived. b, 389 
Kinetic parameters for the binding of C121 IgG, C135 IgG, and CoV-X2 to S trimer and RBD.   390 
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 391 
Extended Data Fig.4 | CoV-X2 binds with low-nanomolar affinity to S protein mutants, including 392 
some that are not recognized by the parental mAbs C121 and C135. a, SPR-derived binding affinities 393 
of CoV-X2, C121 IgG and C135 IgG to several S trimer mutants. b, Mutations tested in (a) are indicated 394 
by yellow spheres on the surface representation of the S trimer. The epitopes of C121 (green) and C135 395 
(blue) are shown.   396 
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 397 
Extended Data Fig.5 | Efficacy of CoV-X2 against B.1.1.7 and B.1.351 variants. a, SPR traces showing 398 
binding of CoV-X2 to the RBD corresponding to wild-type, B.1.1.7 (also known as UK) and B.1.351 (also 399 
known as South African) variants of SARS-CoV-2. b, Residues mutated in the variants are shown as red 400 
spheres on the surface representation of the S trimer. The epitopes of C121 (green) and C135 (blue) are 401 
shown. c, Neutralization of SARS-CoV-2 pseudoviruses expressing wild-type, N501Y and 402 
K417N/E484K/N501Y/R683G (corresponding to South African mutants in the RBD, see Figure 1h) S 403 
protein by CoV-X2. 404 
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 406 
Extended Data Fig.6 | SPR-based avidity assays confirm that CoV-X2 can engage bivalently on a 407 
single RBD. a, CoV-X2 and monoclonal IgGs (C121 or C135) have different binding modes available 408 
when high or low quantities of RBD are immobilized on the surface of the SPR chip. mAbs have avidity 409 
effects at high RBD concentrations due to intermolecular binding, which results in slower dissociation rate 410 
(kd), but not at low RBD concentrations, since bivalent binding to a single RBD is impossible. In contrast, 411 
the bispecific has avidity at both high and low concentrations, since bivalent binding to its two epitopes on 412 
a single RBD is possible. ka is not affected by avidity. b, Experimental confirmation that CoV-X2 engages 413 
bivalently on a single RBD. SPR traces used to determine ka and kd of mAbs, Fab and bispecific at different 414 
concentrations of immobilized RBD (see Fig.1d) are shown. c, Table summarizing the SPR results plotted 415 
in Fig.1d. ka and kd were normalized against the values at the highest RBD concentration. ka and Fab kd were 416 
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unaffected by the RBD concentration, as expected. kd became faster for the monoclonals (loss of avidity) 417 
but less so for the bispecific (avidity maintained due to simultaneous binding to two sites on a single RBD).  418 
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 419 
Extended Data Fig.7 | Generation of the new AAV-hACE2-transduced mouse model for COVID-19. 420 
a, Diagram of the AAV-hACE2 plasmid and corresponding Adeno Associated viral vector. b, Western blot 421 
analysis detecting hACE2 expression in the lungs of one non-transduced control mouse (Ctrl) and 12 mice 422 
transduced with two different doses of AAV-hACE2 viral particles (5x1010 or 1x1011 genome copies (GC)). 423 
Lung tissue was collected 1, 2, or 4 weeks (w) post transduction. Histone H3 was used as control for 424 
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quantification (bottom). c, Preparation of concentrated AAV-hACE2. AAV-hACE2 plasmid was co-425 
transfected with pHelper and AAV Rep/Cap 2/9n vectors into 293AAV cells (see Methods). In order to 426 
increase viral titers, viral particles from both cell lysate and PEG-precipitated growth medium were 427 
ultracentrifuged in discontinuous iodixanol gradient. The silver-stained SDS-PAGE gel shows 14 428 
consecutive fractions: 1-9 represent enriched AAV fractions used for experiments, whereas fractions 10–429 
14 are contaminated with proteinaceous cell debris. Iodixanol was chosen as a density gradient medium 430 
due to its low toxicity in vivo and its easy removal by ultrafiltration. M is protein marker, * are AAV capsid 431 
proteins VP1, VP2, and VP3. d, The amount of AAV particles was estimated by qRT-PCR. The number of 432 
genome copies (GC) expressed as log was calculated from a standard curve. From one 15 cm2 dish, 75 µl 433 
with 2.0x1012 GC/ml were prepared, which is sufficient for hACE2 humanization of 37 mice. e, Kinetic of 434 
lung histopathology in SARS-CoV-2 infected ACE2 humanized mice. Hematoxylin and Eosin-stained 435 
sections showed inflammatory infiltrates composed of lymphocytes, macrophages, neutrophils, and 436 
fibroblasts replacing the alveoli. The size of the affected areas increased over time (area of diffuse alveolar 437 
damage: control <5-10%, 2 dpi <10-30%, 5 dpi 20-80 %, 8 dpi 50-90%). Alveolar septa were thickened in 438 
areas close to infiltrates. In samples collected at 5 and 8 dpi, an increased number of activated macrophages 439 
with foamy cytoplasm (black arrowheads) was seen. AAV-hACE2 transduced, SARS-CoV-2 uninfected 440 
mice were used as control and showed no significant pathology.  441 
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 442 
Extended Data Fig.8 | Post-exposure administration of CoV-X2 protects SARS-CoV-2 infected mice 443 
from disease. Animals were infected intranasally with 104 pfu of SARS-CoV-2 and treated with 444 
250 µg/mouse of either isotype control antibody (n=3) or CoV-X2 (n=2) 12 hours later. Weight loss and 445 
pathological signs were apparent in control but not in CoV-X2 treated animals.  446 
447 
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 448 
Extended Data Fig.9 | Natural SARS-CoV-2 variants in the C121 and C135 epitopes. Summary of 449 
naturally occurring mutations in the C121 (a) or C135 (b) epitopes reported in circulating SARS-CoV-2 450 
(as of January 1, 2021). The location of the mutated residues is shown in red on the RBD structure. C121 451 
and C135 variable regions are in green and blue (PDB ID: 7K8X and 7K8Z respectively). 452 
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 454 
Extended Data Table 1 | Summary of the P values for the mouse protection experiment. Statistical 455 
comparison of body weight differences in animals treated with the individual monoclonal antibodies (C121 456 
or C135), the CoV-X2 bispecific or isotype control at 8 dpi (related to Fig. 2e). P values were determined 457 
with the ANOVA test. Comparison of the entire curves (Fig. 2e) by the One Sample Wilcoxon Test or by 458 
the ANOVA followed by Turkey-Kramer post-test reveals that the isotype control treated group is 459 
statistically different from any of the other groups (CoV-X2, C135, or C121; P<0.05). 460 
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